Tadashi Hirose
Directeur/Bestuurslid bij Prolexys Pharmaceuticals, Inc.
Actieve functies van Tadashi Hirose
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Directeur/Bestuurslid | - | - |
Loopbaan van Tadashi Hirose
Eerdere bekende functies van Tadashi Hirose
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
HITACHI, LTD. | Corporate Officer/Principal | 01-04-1975 | - |
Opleiding van Tadashi Hirose
Keio University | Graduate Degree |
Statistieken
Internationaal
Japan | 3 |
Verenigde Staten | 2 |
Operationeel
Director/Board Member | 1 |
Graduate Degree | 1 |
Undergraduate Degree | 1 |
Sectoraal
Health Technology | 2 |
Consumer Services | 2 |
Producer Manufacturing | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
HITACHI, LTD. | Producer Manufacturing |
Bedrijven in privébezit | 1 |
---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
- Beurs
- Insiders
- Tadashi Hirose
- Ervaring